Table 1.
Characteristics of patients studied
| N (%) | Mean ± SD | Median (Range) | |
|---|---|---|---|
| Age | 57.62 ± 12.9 | 60 (30-83) | |
| <60 years | 12 (46.2) | ||
| ≥60 years | 14 (53.8) | ||
| Menopause | |||
| Premenopausal | 8 (30.8) | ||
| Postmenopausal | 18 (69.2) | ||
| Tumor type | |||
| Inflammatory | 7 (26.9) | ||
| Non-inflammatory | 19 (73.1) | ||
| Tumor size | |||
| T3 | 1 (3.8) | ||
| T4a-T4b | 18 (69.2) | ||
| T4c-T4d | 7 (27.0) | ||
| Nodes | |||
| N0 | 18 (69.2) | ||
| N1-N2 | 8 (30.8) | ||
| Metastasis | |||
| M0 | 24 (92.3) | ||
| M1 | 2 (7.7) | ||
| Bra size | 100 ± 10.6 | 100 (80-120) | |
| <100 | 9 (34.6) | ||
| ≥100 | 17 (65.4) | ||
| Systemic treatment | |||
| Chemotherapy | 4 (15.4) | ||
| Hormonal therapy | 5 (19.2) | ||
| Chemotherapy-hormonal therapy | 17 (65.4) | ||
| Received dose (Gy) | 78.48 ± 5.7 | 81.60 (64.8-81.6) | |
| <81.6 | 7 (26.9) | ||
| ≥81.6 | 19 (73.1) | ||
| Maximum dose (Gy) | 87.36 ± 8.8 | 89.76 (62.8-101.7) | |
| <89.8 | 15 (57.7) | ||
| ≥89.8 | 11 (42.3) |